Repertoire Immune Medicines inks $189m Series B

Repertoire Immune Medicines, a clinical-stage biotech company, has secured $189 million in Series B financing.

13 April 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles